title: Psychiatric disorders after starting dolutegravir: report of four cases.
authors.affiliation: aCentre Régional de Pharmacovigilance Marseille Provence Corse, Service de Pharmacologie Clinique et Pharmacovigilance, Hôpital Sainte-Marguerite, Assistance Publique - Hôpitaux de Marseille, Marseille bPôle Hygiène and Infectiologie, Centre Hospitalier Edmond Garcin, Aubagne cService de Maladies Infectieuses et Tropicales, Hôpital Nord, Assistance Publique - Hôpitaux de Marseille, Marseille, France.
authors.forename: Farid
authors.initials: F
authors.lastname: Kheloufi
authors.forename: Julie
authors.initials: J
authors.lastname: Allemand
authors.forename: Saadia
authors.initials: S
authors.lastname: Mokhtari
authors.forename: Anne
authors.initials: A
authors.lastname: Default
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects* / Q000379:methods*; D018791:CD4 Lymphocyte Count; D005260:Female; D006575:Heterocyclic Compounds, 3-Ring / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced*; D008875:Middle Aged; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D019562:Viral Load; D000099226:Dolutegravir
chemical_list: D019380:Anti-HIV Agents; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D000099226:Dolutegravir